Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS

PharmacoEconomics

Volumn 19, Issue 12, 2001, Pages 1199-1208

  Kempen, J H ^a,b   Frick, K D ^b   Jabs, D A ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; HEALTH CARE COST; HUMAN; INFECTION PREVENTION; INFECTION RISK; PRIORITY JOURNAL; REVIEW;

EID: 0035695171     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119120-00002     Document Type: Review

References (66)

1. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis
2. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine
3. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression
4. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus
5. Ocular manifestations of HIV infection
6. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis
7. The incidence of cytomegalovirus (CMV) antigenemia and CMV disease is reduced by highly active antiretroviral therapy
8. Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: Incidence and outcome over 2 years
9. Effect of highly active antiretroviral therapy on the incidence of HIV-related cytomegalovirus retinitis and retinal detachment
10. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): Clinical findings, diagnosis, and treatment
11. Cytomegalovirus infection in patients with AIDS
12. Gastrointestinal cytomegalovirus disease
13. Cytomegalovirus encephalitis in patients with the acquired immune deficiency syndrome: An autopsy study of 30 cases and a review of the literature
14. Catheter complications in AIDS patients treated for cytomegalovirus retinitis
15. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy
16. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy
17. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy
18. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis
19. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis
20. Effect of potent antiretroviral therapy on recurrent cytomegalovirus retinitis treated with the ganciclovir implant
21. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy
22. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS
23. Foscarnetganciclovir cytomegalovirus retinitis trial. 4. Visual outcomes
24. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS
25. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC peripheral cytomegalovirus trial. A randomized, controlled trial
26. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: A randomized, controlled trial
27. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled trial
28. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant
29. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant
30. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: Long-term results
31. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinitis
32. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis
33. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS
34. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome
35. Fomivirsen: A phosphorothioate oligonucleotide for the treatment of CMV retinitis
36. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS
37. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: Recommendations of the International AIDS Society-USA panel
38. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers
39. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
40. Effect of indinavir and higher CD4+ T-cell count on viral load response after 6 months of highly active antiretroviral therapy
41. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
42. CD4 cell counts at the third month of HAART may predict clinical failure
43. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection
44. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS
45. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals
46. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS
47. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: Baseline CMV load dictates time to disease and survival
48. Summary of the international consensus symposium on advances in the diagnosis, treatment and prophylaxis and cytomegalovirus infection
49. Pre-emptive therapy based on markers of CMV viremia has been useful in the transplant setting
50. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: U.S. Public Health Service (UPSHS) and Infectious Diseases Society of America (IDSA)
51. An economic cost analysis of oral ganciclovir prophylaxis for the prevention of CMV disease
52. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: Oral ganciclovir and CMV polymerase chain reaction testing
53. The cost-effectiveness of preventing AIDS-related opportunistic infections
54. A Monte Carlo simulation of advanced HIV disease: Application to prevention of CMV infection
55. Pre-evaluation of clinical trial data: The case of pre-emptive cytomegalovirus therapy in patients with human immunodeficiency virus
56. Detection of CMV DNA in peripheral blood leukocytes as a long-range harbinger of CMV disease in HIV-infected patients
57. Usefulness of the cytomegalovirus (CMV) antigenemia assay for predicting the occurrence of CMV disease and death in patients with AIDS
58. Comparison of three assays for cytomegalovirus detection in AIDS patients at risk for retinitis
59. Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients
60. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
61. Retinal detachment risk in cytomegalovirus retinitis related to the acquired immune deficiency syndrome
62. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy
63. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: A double-blind, placebo-controlled study